-
公开(公告)号：AT230732T
公开(公告)日：2003-01-15
申请号：AT93103301
申请日：1993-03-02
Applicant: HOECHST AG
Inventor： HEITSCH HOLGER DR , HENNING RAINER DR , WAGNER ADALBERT DR , GERHARDS HERMANN DR , BECKER REINHARD DR , SCHOELKENS BERNWARD PROF DR
IPC: A61K31/415 , A61K31/4164 , A61K31/64 , A61P9/10 , A61P9/12 , C07D233/84 , C07D233/86 , C07D233/90
Abstract: Compounds of the formula (I) in which R is, for example, ethyl, R is, for example, methyl, n is, for example, zero, R is, for example, COOH and R is, for example, SO2NHCONHCH3 are highly active antagonists of angiotensin II receptors.
-
82.发明专利
公开(公告)号：GR3030022T3
公开(公告)日：1999-07-30
申请号：GR990401103
申请日：1999-04-21
Applicant: HOECHST AG
Inventor： BECKER REINHARD DR , HENNING RAINER DR , TEETZ VOLKER DR , URBACH HANSJOERG DR
IPC: A61K38/55 , A61K31/275 , A61K31/277 , A61K31/40 , A61K31/401 , A61K31/41 , A61K31/425 , A61K31/455 , A61K31/47 , A61K31/55 , A61K45/06 , A61P3/00 , A61P3/14 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00
Abstract: An angiotensin converting enzyme inhibitor (I) can be used in combination with Ca antagonists (III) in the prevention and therapy of proteinuria. Pref. (A) Ramipril and felodipine; (B) Ramipril and 4-(2,3-dichlorophenyl) -2,6-dimethyl-3- (1,2,4-oxadiazol-5-yl) -S-isopropoxy carbonyl-1,4-dihydropyridine (IIb), (c) Trandolapril and felodipine; (D) Trandolapril and (IIb), (E) Trandolapril and Verapamil; (F) Quinapril and felodipine; (G) Quinapril and (IIIb) or the physiologically acceptable salts of these components.
-
公开(公告)号：AT165351T
公开(公告)日：1998-05-15
申请号：AT91122406
申请日：1992-01-01
Applicant: HOECHST AG
Inventor： WAGNER ADALBERT DR , ENGLERT HEINRICH DR , KLEEMANN HEINZ-WERNER DR , GERHARDS HERMANN DR , SCHOELKENS BERNWARD PROF DR , BECKER REINHARD DR , LINZ WOLFGANG DR , CAILLE JEAN-CLAUDE , VEVERT JEAN-PAUL
IPC: A61K31/40 , A61K31/415 , A61K31/425 , A61K31/435 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/505 , A61K31/535 , A61K31/54 , A61K31/64 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , C07D207/34 , C07D207/36 , C07D233/54 , C07D233/66 , C07D233/68 , C07D233/70 , C07D233/84 , C07D233/90 , C07D249/02 , C07D255/02 , C07D257/02 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D453/02 , C07D521/00
Abstract: Azole derivative of the general formula (I) in which A, L, O, R , X, Y, Z and q have the meanings given, a process for their preparation, pharmaceutical preparations and the use of the compounds are described. Azole derivatives of the formula I where the symbols have, for example, the following meanings: R = (C2-C10)-alkyl Z = nitrogen X and Y = independently of one another CR L = -CH2- q = zero or 1 A = biphenyl radical which is substituted, for example, by R R = halogen or hydrogen R = SO2-NH-CO-OR and R = phenyl, are highly active antagonists of angiotensin II receptors.
-
公开(公告)号：CZ281983B6
公开(公告)日：1997-04-16
申请号：CS381192
申请日：1992-12-21
Applicant: HOECHST AG
Inventor： HEITSCH HOLGER DR , HENNING RAINER DR , WAGNER ADALBERT DR , GERHARDS HERMANN DR , BECKER REINHARD DR , SCHOLKENS BERNWARD PROF DR
IPC: A61K31/415 , A61K31/4164 , A61K31/64 , A61P9/10 , A61P9/12 , C07D233/84 , C07D233/86 , C07D233/90
Abstract: Compounds of the formula (I) in which R is, for example, ethyl, R is, for example, methyl, n is, for example, zero, R is, for example, COOH and R is, for example, SO2NHCONHCH3 are highly active antagonists of angiotensin II receptors.
-
公开(公告)号：DK0488059T3
公开(公告)日：1996-01-02
申请号：DK91119892
申请日：1991-11-21
Applicant: HOECHST AG
Inventor： TEETZ VOLKER DR , BECKER REINHARD DR , HENNING RAINER DR , URBACH HANSJOERG DR
IPC: A61K38/55 , A61K31/275 , A61K31/277 , A61K31/40 , A61K31/401 , A61K31/41 , A61K31/425 , A61K31/455 , A61K31/47 , A61K31/55 , A61K45/06 , A61P3/00 , A61P3/14 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , A61K37/64
Abstract: An angiotensin converting enzyme inhibitor (I) can be used in combination with Ca antagonists (III) in the prevention and therapy of proteinuria. Pref. (A) Ramipril and felodipine; (B) Ramipril and 4-(2,3-dichlorophenyl) -2,6-dimethyl-3- (1,2,4-oxadiazol-5-yl) -S-isopropoxy carbonyl-1,4-dihydropyridine (IIb), (c) Trandolapril and felodipine; (D) Trandolapril and (IIb), (E) Trandolapril and Verapamil; (F) Quinapril and felodipine; (G) Quinapril and (IIIb) or the physiologically acceptable salts of these components.
-
Patent Agency Ranking86.发明专利
公开(公告)号：GR3017588T3
公开(公告)日：1995-12-31
申请号：GR950402701
申请日：1995-09-29
Applicant: HOECHST AG
Inventor： BECKER REINHARD DR , HENNING RAINER DR , TEETZ VOLKER DR , URBACH HANSJOERG DR
IPC: A61K38/55 , A61K31/275 , A61K31/277 , A61K31/40 , A61K31/401 , A61K31/41 , A61K31/425 , A61K31/455 , A61K31/47 , A61K31/55 , A61K45/06 , A61P3/00 , A61P3/14 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00
Abstract: An angiotensin converting enzyme inhibitor (I) can be used in combination with Ca antagonists (III) in the prevention and therapy of proteinuria. Pref. (A) Ramipril and felodipine; (B) Ramipril and 4-(2,3-dichlorophenyl) -2,6-dimethyl-3- (1,2,4-oxadiazol-5-yl) -S-isopropoxy carbonyl-1,4-dihydropyridine (IIb), (c) Trandolapril and felodipine; (D) Trandolapril and (IIb), (E) Trandolapril and Verapamil; (F) Quinapril and felodipine; (G) Quinapril and (IIIb) or the physiologically acceptable salts of these components.
-
公开(公告)号：CZ8800892A3
公开(公告)日：1994-12-15
申请号：CS89288
申请日：1988-02-12
Applicant: HOECHST AG
Inventor： URBACH HANSJORG DR , HENNING RAINER DR , SCHOLKENS BERNWARD DR , BECKER REINHARD DR
IPC: C07D223/32 , A61K31/395 , A61K31/445 , A61K31/55 , A61K38/00 , A61P9/00 , A61P9/12 , A61P27/02 , A61P27/06 , A61P43/00 , C07D225/04 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07K5/02
CPC classification number: C07K5/0222 , A61K38/00
-
公开(公告)号：AT98130T
公开(公告)日：1993-12-15
申请号：AT89109209
申请日：1989-05-23
Applicant: HOECHST AG
-
公开(公告)号：DE3780753D1
公开(公告)日：1992-09-03
申请号：DE3780753
申请日：1987-09-29
Applicant: HOECHST AG
Inventor： BECKER REINHARD DR , HENNING RAINER DR , RUEGER WOLFGANG DR , TEETZ WOLFGANG DR , URBACH HANSJOERG DR
IPC: A61K31/40 , A61K31/401 , A61K31/435 , A61K31/44 , A61K38/05 , A61K38/55 , A61K45/06 , A61P3/00 , A61P3/14 , A61P9/12 , A61P43/00 , A61K37/64
Abstract: Pharmaceutical prepn. contain (1) an angiotensin converting enzyme (NCE) inhibitor of formula (I) or a physiologically tolerable salt thereof and (2) a calc1um antagonist or a physiologically tolerable salt thereof are new. In (I), N = 1 or 2; R = H, an opt. substd. 1-8C aliphatic, 3-9C alicyclic, 6-12C aromatic, 7-14C araliphatic or 7-14C alicyclic-aliphatic residue, or a residue ORa or SRa; Ra = opt. substd. 1-4C aliphatic or 6-12C aromatic residue, or an opt. substd. heteroaromatic residue with 5-12 ring atoms; R1 = H, an opt. substd. 1-6C aliphatic, 3-9C alicyclic, 4-13C alicyclic-aliphatic, 6-12C aromatic or 7-16 araliphatic residue, an opt. substd. heteroaromatic residue with 5-12 ring atoms, or the side-chain (protected if necessary) of a naturally occuring alpha-amino acid; R2,R3 = H, or an opt. substd. 1-6C aliphatic, 3-9C alicyclic, 6-12C aromatic or 7-16C araliphatic residue; R4,R5 = (together with the atoms carrying them) heterocyclic bi- or tricyclic ring system with 5-15C-atoms. (B) Also new are products contg. (1) an ACE inhibitor of formula (I) or a physiologically tolerable salt thereof and (2) a calcium antagonist or a physiologically tolerable salt thereof for simultaneous, separate or sequential application in the treatment of hypertension.
-
公开(公告)号：AT78697T
公开(公告)日：1992-08-15
申请号：AT87114164
申请日：1987-09-29
Applicant: HOECHST AG
-
-
-
-
-
-
-
-
-
Search Results
105
records
(took 0.021 seconds)
